Cardiovascular DiseasesSCAPIS2NCT06679777
Swedish CArdioPulmonary bioImage Study 2
An observational study of Cardiovascular Diseases and Lung Diseases, run by Karolinska Institutet at 6 sites in Sweden.
Trial summary
In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases, Lung Diseases
- How many people
- 30,154 participants
- Where
- 6 sitesSweden
- Study dates
- 15 Jan 2024to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms. In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.
Who may be able to join
- Participated in SCAPIS 1.
Who cannot join
- Individuals who have withdrawn their informed consent during or after SCAPIS 1.
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
Sweden6 sites, 6 recruiting
- Recruiting
Gothenburg University
Gothenburg
Göran Bergström, +46-31-7860000, goran.bergstrom@hjl.gu.se
- Recruiting
Linköping University
Linköping
Carl Johan Östgren, +46-13-281000, carl.johan.ostgren@liu.se
- Recruiting
Lund University
Lund
Gunnar Engström, +46-46-2220000, gunnar.engstrom@med.lu.se
- Recruiting
Karolinska Institutet
Stockholm
Tomas Jernberg, +46-8-12355000, tomas.jernberg@regionstockholm.se
- Recruiting
Umeå Universitet
Umeå
Anders Blomberg, +46-90-7865000, anders.blomberg@umu.se
- Recruiting
Uppsala University
Uppsala
Andrei.malinovschi@medsci.u Malinovschi, andrei.malinovschi@medsci.uu.se
About this study
In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms.
In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.
Read the detailed description
The overall aim of SCAPIS is to improve prediction and prevention of cardiovascular and lung disease in the general population by identifying novel risk markers. This is also the purpose of SCAPIS 2, which further aims to gain important insights into risk factors and longitudinal development of heart, vascular and lung diseases such as atherosclerosis and chronic obstructive pulmonary disease. SCAPIS 2 will investigate 15,000 study participants approximately 8-10 years after the baseline examination SCAPIS 1.
The five overall objectives of SCAPIS 2 are:
- To determine characteristics related to the natural progression of atherosclerosis over 8-10 years.
- To evaluate characteristics related to pathological cardiovascular aging over 8-10 years.
- To determine characteristics related to the natural progression of lung function over 8-10 years.
- To determine risk factors associated with the progression of coronary atherosclerosis and the development of impaired lung function or structural changes of the lungs.
- To compare outcome in individuals who are invited to SCAPIS 2 and those not invited.
SCAPIS 2 will recruit approximately 15,000 subjects randomly selected from the baseline examination (SCAPIS 1) study population approximately 8-10 years after their initial participation. During the SCAPIS 1 random samples of men and women aged 50-64 years were drawn from each recruitment area in the Swedish population registry until approximately 30 000 subjects were included. The final number was 30 154 subjects with an even sex and age distribution. The original recruitment process ensured that the study population in SCAPIS 1 was representative for the Swedish population in general.
An invitation letter with brief information about SCAPIS 2 will be sent to randomly selected individuals by mail, including phone number and e-mail address to the study center. The invitation letter will refer to a study webpage where the subjects can indicate if they are interested in participating in SCAPIS 2 and read the subject information in advance (voluntary). The invitation also includes contact information to the study center to be used if the subject prefers to not use the web page or has questions. Subjects that have moved since their participation in SCAPIS 1 will be invited to the same study center as their baseline examination.
The examinations will be performed during 2-3 days within approximately 2 weeks. Whenever possible, all visits should be performed within a period of 4 weeks. Examinations that are common for all sites include:
- Medical history
- Anthropometry
- Clinical chemistry/hematology: Hb, p-Glucose, HbA1c, s-TG, s- Cholesterol, LDL, HDL, creatinine, detailed leukocyte count)
- Biobank sampling (plasma, serum, whole blood, and urine)
- Spirometry
- CO uptake
- Questionnaires
- Accelerometry (hip)
- Electrocardiogram (ECG)
- Heart rate
- Blood pressure
- Computed tomography (CT)
- Body composition
- Lung tissue
- Coronary artery calcium score (CACS)
- Coronary computed tomography angiography (CCTA)
All subjects will be fasting overnight (at least 8 hours) before the first visit. If a subject has not been fasting overnight, blood sampling should be rescheduled and performed preferably at an extra visit but no later than Visit 2. For subjects with elevated plasma glucose levels, an overnight fasting glucose measurement will be repeated.
Subjects should be instructed to take their regular medication as usual also when fasting. The only medication that should not be taken is medication for diabetes, per oral as well as injections. Subjects with diabetes should be fasting as all other subjects and should bring their medication to take when having breakfast at the clinic. To obtain standardized conditions for the CT examination, subjects are recommended to be fasting for at least 4 hours before intake of a standardized meal. The standardized meal should be consumed 2 hours before the CT scan.
All clinical findings and assessment of risk should be taken care of according to current guidelines and SCAPIS manual.
- Conditions
- Cardiovascular Diseases, Lung Diseases
- Medical subject headings
- Cardiovascular Diseases, Lung Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiovascular death, non-fatal myocardial infarction or stroke.
Cardiovascular death, non-fatal myocardial infarction or stroke.
Measured: Through study completion, an average of 5 years
Secondary outcomes (8)
Cardiovascular death or non-fatal myocardial infarction
Cardiovascular death or non-fatal myocardial infarction
Measured: Through study completion, an average of 5 years
Cardiovascular death
Cardiovascular death
Measured: Through study completion, an average of 5 years
Myocardial infarction (fatal or non-fatal)
Myocardial infarction (fatal or non-fatal)
Measured: Through study completion, an average of 5 years
Stroke (fatal or non-fatal)
Stroke (fatal or non-fatal)
Measured: Through study completion, an average of 5 years
Death (all-cause)
Death (all-cause)
Measured: Through study completion, an average of 5 years
Unstable angina requiring revascularization
Unstable angina requiring revascularization
Measured: Through study completion, an average of 5 years
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD)
Measured: Through study completion, an average of 5 years
Lung cancer
Lung cancer
Measured: Through study completion, an average of 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2024
- Study start15 Jan 2024
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30,154 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Lund University, Uppsala University, Umeå University, Linkoeping University, Göteborg University
- Responsible party
- Principal investigator, Tomas Jernberg, Karolinska Institutet
- Investigators
- Carl Johan Östgren, PhD, Principal investigator, Linkoeping University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06679777
- Sponsor's protocol ID
- 2024-01
- Acronym
- SCAPIS2
- Status last verified
- Nov 2024
- First submitted
- 4 Nov 2024
- Last updated
- 7 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data can be shared if approved the Swedish Ethical Review Authority and authority responsible for personal data
Publications
Bergstrom G, Berglund G, Blomberg A, Brandberg J, Engstrom G, Engvall J, Eriksson M, de Faire U, Flinck A, Hansson MG, Hedblad B, Hjelmgren O, Janson C, Jernberg T, Johnsson A, Johansson L, Lind L, Lofdahl CG, Melander O, Ostgren CJ, Persson A, Persson M, Sandstrom A, Schmidt C, Soderberg S, Sundstrom J, Toren K, Waldenstrom A, Wedel H, Vikgren J, Fagerberg B, Rosengren A. The Swedish CArdioPulmonary BioImage Study: objectives and design. J Intern Med. 2015 Dec;278(6):645-59. doi: 10.1111/joim.12384. Epub 2015 Jun 19.
PubMed 26096600
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Swedish CArdioPulmonary bioImage Study 2
- ClinicalTrials.gov ID
- NCT06679777
- Acronym / sponsor ID
- SCAPIS2 / 2024-01
- Conditions
- Cardiovascular Diseases, Lung Diseases
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30,154 participants (estimated)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Lund University, Uppsala University, Umeå University, Linkoeping University, Göteborg University
- Study start
- 15 Jan 2024 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 7 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms.
In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.
Detailed description
The overall aim of SCAPIS is to improve prediction and prevention of cardiovascular and lung disease in the general population by identifying novel risk markers. This is also the purpose of SCAPIS 2, which further aims to gain important insights into risk factors and longitudinal development of heart, vascular and lung diseases such as atherosclerosis and chronic obstructive pulmonary disease. SCAPIS 2 will investigate 15,000 study participants approximately 8-10 years after the baseline examination SCAPIS 1.
The five overall objectives of SCAPIS 2 are:
- To determine characteristics related to the natural progression of atherosclerosis over 8-10 years.
- To evaluate characteristics related to pathological cardiovascular aging over 8-10 years.
- To determine characteristics related to the natural progression of lung function over 8-10 years.
- To determine risk factors associated with the progression of coronary atherosclerosis and the development of impaired lung function or structural changes of the lungs.
- To compare outcome in individuals who are invited to SCAPIS 2 and those not invited.
SCAPIS 2 will recruit approximately 15,000 subjects randomly selected from the baseline examination (SCAPIS 1) study population approximately 8-10 years after their initial participation. During the SCAPIS 1 random samples of men and women aged 50-64 years were drawn from each recruitment area in the Swedish population registry until approximately 30 000 subjects were included. The final number was 30 154 subjects with an even sex and age distribution. The original recruitment process ensured that the study population in SCAPIS 1 was representative for the Swedish population in general.
An invitation letter with brief information about SCAPIS 2 will be sent to randomly selected individuals by mail, including phone number and e-mail address to the study center. The invitation letter will refer to a study webpage where the subjects can indicate if they are interested in participating in SCAPIS 2 and read the subject information in advance (voluntary). The invitation also includes contact information to the study center to be used if the subject prefers to not use the web page or has questions. Subjects that have moved since their participation in SCAPIS 1 will be invited to the same study center as their baseline examination.
The examinations will be performed during 2-3 days within approximately 2 weeks. Whenever possible, all visits should be performed within a period of 4 weeks. Examinations that are common for all sites include:
- Medical history
- Anthropometry
- Clinical chemistry/hematology: Hb, p-Glucose, HbA1c, s-TG, s- Cholesterol, LDL, HDL, creatinine, detailed leukocyte count)
- Biobank sampling (plasma, serum, whole blood, and urine)
- Spirometry
- CO uptake
- Questionnaires
- Accelerometry (hip)
- Electrocardiogram (ECG)
- Heart rate
- Blood pressure
- Computed tomography (CT)
- Body composition
- Lung tissue
- Coronary artery calcium score (CACS)
- Coronary computed tomography angiography (CCTA)
All subjects will be fasting overnight (at least 8 hours) before the first visit. If a subject has not been fasting overnight, blood sampling should be rescheduled and performed preferably at an extra visit but no later than Visit 2. For subjects with elevated plasma glucose levels, an overnight fasting glucose measurement will be repeated.
Subjects should be instructed to take their regular medication as usual also when fasting. The only medication that should not be taken is medication for diabetes, per oral as well as injections. Subjects with diabetes should be fasting as all other subjects and should bring their medication to take when having breakfast at the clinic. To obtain standardized conditions for the CT examination, subjects are recommended to be fasting for at least 4 hours before intake of a standardized meal. The standardized meal should be consumed 2 hours before the CT scan.
All clinical findings and assessment of risk should be taken care of according to current guidelines and SCAPIS manual.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms. In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.
Key inclusion criteria (1 listed)
- Participated in SCAPIS 1.
Key exclusion criteria (1 listed)
- Individuals who have withdrawn their informed consent during or after SCAPIS 1.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cardiovascular death, non-fatal myocardial infarction or stroke.
Time frame: Through study completion, an average of 5 years
Cardiovascular death, non-fatal myocardial infarction or stroke.
8 secondary outcomes
Cardiovascular death or non-fatal myocardial infarction
Time frame: Through study completion, an average of 5 years
Cardiovascular death
Time frame: Through study completion, an average of 5 years
Myocardial infarction (fatal or non-fatal)
Time frame: Through study completion, an average of 5 years
Stroke (fatal or non-fatal)
Time frame: Through study completion, an average of 5 years
Death (all-cause)
Time frame: Through study completion, an average of 5 years
Unstable angina requiring revascularization
Time frame: Through study completion, an average of 5 years
Chronic obstructive pulmonary disease (COPD)
Time frame: Through study completion, an average of 5 years
Lung cancer
Time frame: Through study completion, an average of 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2024.
- Background: PubMed 26096600Bergstrom G, Berglund G, Blomberg A, Brandberg J, Engstrom G, Engvall J, Eriksson M, de Faire U, Flinck A, Hansson MG, Hedblad B, Hjelmgren O, Janson C, Jernberg T, Johnsson A, Johansson L, Lind L, Lofdahl CG, Melander O, Ostgren CJ, Persson A, Persson M, Sandstrom A, Schmidt C, Soderberg S, Sundstrom J, Toren K, Waldenstrom A, Wedel H, Vikgren J, Fagerberg B, Rosengren A. The Swedish CArdioPulmonary BioImage Study: objectives and design. J Intern Med. 2015 Dec;278(6):645-59. doi: 10.1111/joim.12384. Epub 2015 Jun 19.
- websiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Individual participant data can be shared if approved the Swedish Ethical Review Authority and authority responsible for personal data
Related trials for Cardiovascular Diseases
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 1/2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Carl Johan Östgren, PhD principal investigator
Linkoeping University
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Lung Diseases, run by Karolinska Institutet at 6 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tomas Jernberg, PhD (+46-70-1671474, tomas.jernberg@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiovascular death, non-fatal myocardial infarction or stroke. (time frame: Through study completion, an average of 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06679777, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2024.